The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> April 21, 2017

Interview with the Co-Founder and CEO: GlycoMimetics, Inc. (NASDAQ:GLYC)

King, Rachel K.
Rachel K. King is Co-Founder and Chief Executive Officer of GlycoMimetics, Inc. Before founding the company, she was an Executive in Residence at New Enterprise Associates, one of the nation’s leading venture capital firms.  Mrs. King came to New Enterprise Associates after serving as a Senior Vice President of Novartis Corporation. Before joining Novartis Corporation, Mrs. King spent 10 years with Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis Corporation. After the sale, she was named CEO and ran Genetic Therapy, Inc. as a wholly owned subsidiary of Novartis Corporation. Mrs. King also worked previously at ALZA Corporation in Palo Alto, California, and at Bain and Company in Boston. She received her B.A. from Dartmouth College and her MBA from Harvard Business School. Mrs. King is the past Chair of the Emerging Companies Governing Board and of the full board of the Biotechnology Innovation Organization — BIO — and continues to serve on BIO’s executive committee. She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley, and now serves on the board of directors of Warp Drive Bio, a Third Rock Ventures-funded biotechnology company based in Cambridge, and of the University of Maryland BioPark. Profile
TWST: Can you briefly describe what the company is and describe its core technology?

Mrs. King: The core technology enables us to target carbohydrate-related

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
AI Opportunities Expand to Industrial, Utilities and Energy Sectors
India Fund Manager Expects Discretionary Spending to Grow
Inefficiency in Ex-US Markets Creates Opportunity to Buy at a Discount
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy